Trials / Unknown
UnknownNCT00466284
Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer
Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (planned)
- Sponsor
- Grupo Gallego de Cancer de Pulmon · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients will be treated. STUDY OBJECTIVES Primary: Objective response rate Secondary: Progression free survival, Overall survival and Safety of Tarceva
Detailed description
Study Design: Phase II trial, open label, non-randomized and multicenter. Expected total enrollment: 46 Study start: January, 2006 Study completation: January, 2008
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva (erlotinib) |
Timeline
- Start date
- 2006-01-01
- First posted
- 2007-04-27
- Last updated
- 2007-04-27
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00466284. Inclusion in this directory is not an endorsement.